LGALS9 and B-cell non-Hodgkin lymphoma: In contrast, the sensitivity of B cell lymphoma cell lines for Gal-9 significantly correlated with basal protein expression levels of LC3B-I, whereby cell lines with lower basal LC3B-I levels were more sensitive toward Gal-9 treatment than cell lines with higher LC3B-I levels (Figure 4A).